Navigation Links
Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:7/24/2008

can be disconcerting to patients as they often require the use of restraints, and can be dangerous to the medical personnel while they attempt to inject the patient. IM injections can also take up to 60 minutes to work. Oral tablets provide convenience of dosing alternatives, but have a slower onset of action. This market research has also identified speed of onset as an important factor that affects the choice of therapy for treating acute agitation. Alexza believes that many patients with schizophrenia or bipolar disorder can make informed decisions regarding their treatment in an acute agitative state and would prefer a rapid-acting, noninvasive treatment.

In summary, Alexza believes there is a significant unmet medical need for an acute agitation treatment option that will provide a fast onset of effect, that is noninvasive and safer to administer, and that allows patients to be active participants in choosing acceptable treatment options.

About AZ-004 (Staccato loxapine)

AZ-004 is the combination of Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known generally as antipsychotics. The Staccato system is a hand-held, chemically-heated, single dose inhaler designed to generate and deliver excipient-free drug aerosol for deep lung delivery that results in IV-like pharmacokinetics. Alexza has completed four clinical trials with AZ-004, including a 50 subject Phase 1 study in healthy volunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and PK study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in agitated schizophrenic patients. Alexza projects that the initial results from the first Phase 3 study will be reported before the end of September 2008.

The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measured by a reduction in the sig
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
4. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
11. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... MONICA, Calif. , Sept. 17, 2014  Dr. ... is at the White House today for National Recovery ... 46 that consumer advocates released today. Consumer advocates were ... woman who spoke out after losing her fiancée ... discovering that the doctor had a history of crack ...
Breaking Medicine Technology:VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3
... 18, 2011 Adeona Pharmaceuticals, Inc. (Amex: ... central nervous system diseases, announced today that it will ... 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington ... Arbor, Adeona,s management team welcomes shareholders, potential investors and ...
... Companion Animal Health has launched its second product in ... + milbemycin oxime), a broad-spectrum parasiticide that kills fleas ... flea infestations, the prevention of heartworm disease and the ... infections in dogs and puppies 8 weeks and older, ...
Cached Medicine Technology:Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 2Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 3Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... its team and surgeon partners in Less Exposure ... joining SpineFrontier, Tamara authored an extensive education curriculum ... a Masters in Science in Organizational Leadership, and ... industries for eleven years. Bringing her to the ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach ... beauty has to be seen to be believed and ... order to be used. Together, both lead to hearts ... how to do both. , Dr. Clark ... Healing Hearts system, which provides professional guidance on dealing ...
(Date:9/18/2014)... Specialty Teleradiology LLC, a provider of teleradiology services ... achieved Meaningful Use and increased operational efficiency since ... developed by RamSoft. , Before implementing PowerServer ... PACS and a RIS that was built in-house. ... oncology to other subspecialties, they needed a robust, ...
(Date:9/18/2014)... 2014 N-Zyme Scientifics LLC achieved a ... first product a mere 8 months after company startup. ... performance glycan release enzyme used in the “Biologics” industry ... basis for tissue pathology on Mass Spec devices. PRIME™ ... the North American market (PNGase F PRIMETM). N-Zyme ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2
... latest research unhealthy ways of expressing anger are associated ... //expressing anger." According to past research, stress can also ... not practice healthy anger or stress management may be ... adolescents, ages 14 to 17, for three years. In ...
... New research shows one virus could help fight another. ... // hepatitis G , may hold a key ... ,Researchers analyzed results from the Multicenter Acquired ... large group of HIV-infected men in the United States ...
... put a woman at increased risk of developing asthma, report ... obstructive pulmonary disease (COPD) risk. ,The incidence of both ... 5 percent to 8 percent of Americans have asthma, and ... since 1982. Since the prevalence of asthma tends to change ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... is showing promising results.For the past decade, researchers // ... immunotoxin is bioengineered and consists of only the most ... commonly used to fight leukemia. One of those immunotoxins, ... study. ,Researchers say in a phase I study, ...
... estimates that 40 million people are infected with the ... In some African countries, 40 percent of pregnant women ... caught HIV. ,In impoverished areas where the ... one-time treatment for HIV-infected pregnant women to keep them ...
Cached Medicine News:Health News:Drug to stop HIV spread to babies may Indirectly harm The Mother 2
... Alliance Catheter Delivery System (CDS) ... stabilization of the Aescula LV ... has a patented coronary sinus ... and easy access to the ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Pipette* provides quick, convenient, repetitive dispensing ... Combitips have a polyethylene plunger and ... for use with most reagents. ... Five separate volumes can be selected ...
Medicine Products: